FOR RESEARCH USE ONLY
CJC+Ipamorelin

CHEMICAL PROPERTIES

CAS NUMBERN/A — Combination
MOLECULAR WEIGHTN/A — Combination
MOLECULAR FORMULACJC-1295 (No DAC) + Ipamorelin

PHYSICAL PROPERTIES

APPEARANCEWhite lyophilized powder in sealed borosilicate glass vial.
SEQUENCECJC-1295 No DAC + Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂)

CJC+Ipamorelin

CJC+Ipamorelin combines a GHRH analogue (CJC-1295 No DAC) with a selective GHS/ghrelin receptor agonist (Ipamorelin) in a single preparation. The two peptides work through complementary but distinct receptor systems — GHRH-R and GHSR-1a respectively — and are frequently studied together in GH axis research.

1
Free shipping on orders over $150
2-day delivery
LOT NUMBERLMO-0626-CI-010
REPORT NO.RPT-20007
HPLC PURITY98.60%

7× Independently Tested

HPLC PurityIndependent lab
IdentitySequence confirmed
Net ContentExact mg verified
SterilityContamination-free
EndotoxinsLAL tested
Heavy MetalsICP-MS screened
Batch ConsistencyLot-to-lot stability
TESTED

RESEARCH USE ONLY

This compound is sold strictly for in vitro research and laboratory use. Not for human or animal consumption. Not a drug, food, or supplement. By purchasing you confirm you are a qualified researcher and will use this compound in compliance with all applicable laws. Must be 21 or older.

RESEARCH

Pulsatile Secretion of Growth Hormone Persists During Continuous Stimulation by CJC-1295
Ionescu M, Frohman LA. · Journal of Clinical Endocrinology & Metabolism · 2006
Human trial establishing that CJC-1295 produces sustained, pulsatile GH and IGF-1 elevation — foundational evidence for the GHRH component of this blend.
PMID 17018654
Ipamorelin, the First Selective Growth Hormone Secretagogue
Raun K, Hansen BS, Johansen NL, et al. · European Journal of Endocrinology · 1998
Establishes Ipamorelin as a selective GHS-R1a agonist without cortisol or prolactin effects, providing the complementary GH pulse axis for the CJC/Ipamorelin dual-mechanism blend.
PMID 9849822
Synergistic Effects of GHRH and GHRP on Growth Hormone Secretion In Vivo
Bowers CY, Sartor AO, Reynolds GA, Badger TM. · Endocrinology · 1991
Early study demonstrating that co-administration of GHRH and a GHRP produces a synergistic GH response significantly greater than either compound alone — the mechanistic basis for combined secretagogue research.
PMID 1846653

LAB RESULTS

LOT LMO-0626-CI-010 · CURRENT

Certificate of Analysis

PURITY
98.60%
CAS
N/A — Combination
MW
N/A — Combination
APPEARANCE
White lyophilized powder in sealed borosilicate glass vial.
VERIFIED

Third-Party Report

TESTING LABIndependent Analytics LLC
TEST DATEJanuary 2025
METHODS USED
HPLCMSAAA
RESEARCH APPLICATIONS

What the literature covers.

  • Dual GHRH-R and GHSR-1a pathway research in a single preparation
  • Complementary GH secretagogue mechanism studies
  • Combined pulsatile and tonic GH release pathway investigations
  • Widely referenced combination in preclinical GH axis research literature

All compounds sold by Lumo are intended strictly for in vitro research and laboratory use only. These products are NOT intended for human consumption, medical, veterinary, or household use. By purchasing from Lumo, you acknowledge that you are a qualified researcher or institution and will use these products solely for research purposes in compliance with all applicable laws and regulations.

L-003

Stay current.

New lot releases, research updates, and product announcements.

Unsubscribe anytime. Research use communications only.

Research Use Only · Not for Human Consumption · For Laboratory Research Purposes Only

Your Cart

● All items for research use only. Not for human consumption.

Your cart is empty

Add compounds to get started